Rare Urea Cycle Disorder ASLD Demands Lifelong Vigilance and Precision Care
Argininosuccinate lyase deficiency disrupts ammonia processing, causing brain, liver, and vascular damage across a lifetime.
Summary
Argininosuccinate lyase deficiency (ASLD) is a rare inherited urea cycle disorder causing toxic ammonia buildup. It presents either as a life-threatening neonatal crisis or as subtle late-onset cognitive, behavioral, and organ complications. Long-term consequences include intellectual disabilities, ADHD, liver disease, hypertension, and brittle hair. Diagnosis relies on detecting elevated argininosuccinate in blood or urine, or identifying mutations in the ASL gene. Management requires protein-restricted diets, arginine supplementation, nitrogen-scavenging drugs, and emergency protocols for metabolic crises. Severe cases may require dialysis or liver transplantation. Inherited in an autosomal recessive pattern, ASLD carries a 25% recurrence risk for siblings, making genetic counseling and newborn screening essential for affected families.
Detailed Summary
Argininosuccinate lyase deficiency (ASLD) is an inborn error of urea cycle metabolism caused by biallelic pathogenic variants in the ASL gene. The urea cycle is the primary biochemical pathway for disposing of nitrogen waste as urea, and its disruption leads to hyperammonemia — a dangerous accumulation of ammonia in the blood that is particularly toxic to the brain and nervous system.
ASLD presents across a wide clinical spectrum. Neonatal-onset disease manifests within days of birth with vomiting, lethargy, poor feeding, and rapid progression to seizures, coma, and death if untreated. Late-onset forms may appear more insidiously, with episodic hyperammonemia triggered by infection or stress, or with chronic neurocognitive impairments — including learning disabilities, ADHD, and developmental delays — even without overt ammonia crises.
Long-term complications extend well beyond the brain. Liver disease ranging from hepatomegaly to cirrhosis, systemic hypertension, hypokalemia, and trichorrhexis nodosa (brittle hair) are recognized features. These multisystem manifestations underscore that ASLD is not merely a metabolic emergency but a chronic, progressive condition requiring coordinated multidisciplinary care.
Management centers on reducing ammonia production through dietary protein restriction and arginine supplementation, while nitrogen-scavenging medications provide additional protection. Acute decompensations require aggressive intervention including intravenous glucose, lipids, and nitrogen scavengers, with hemodialysis reserved for severe cases. Liver transplantation is an option for refractory disease, though it does not fully resolve neurological risks.
Genetic counseling is critical: ASLD follows autosomal recessive inheritance, giving each sibling of an affected child a 25% chance of being affected. Prenatal and preimplantation genetic testing are available once familial variants are identified, and newborn screening programs are essential for early intervention before irreversible harm occurs.
Key Findings
- ASLD causes hyperammonemia via urea cycle failure, presenting as neonatal crisis or late-onset cognitive and organ dysfunction.
- Long-term complications include liver disease, systemic hypertension, ADHD, intellectual disabilities, and brittle hair.
- Diagnosis confirmed by elevated argininosuccinate in plasma/urine or biallelic ASL gene mutations.
- Treatment combines protein restriction, arginine supplementation, nitrogen-scavenging drugs, and dialysis for severe episodes.
- Autosomal recessive inheritance means 25% sibling recurrence risk; prenatal testing is available.
Methodology
This is a GeneReviews clinical reference entry, not an original research study. It synthesizes existing evidence on ASLD diagnosis, management, and genetics from the medical literature and expert consensus. It was originally published in 2011 and last updated in August 2025.
Study Limitations
As a review article rather than primary research, this entry does not present new clinical trial data or outcomes statistics. Evidence quality varies across the recommendations cited. The rarity of ASLD limits the size of available patient cohorts, potentially affecting the generalizability of management guidelines.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
